A lipoprotein (a) (Lp[a]) assay has been granted breakthrough device designation to expand identification of patients with elevated Lp(a) and genetic predispositions to cardiovascular disease.
Understanding epigenetics gives healthcare professionals and researchers insights into the molecular processes that influence health and diseases, potentially leading to better disease prevention, early detection, and more targeted treatments.
This new tool, using an automated analysis of different parts of the body, could help clinicians to address previously unmet needs for treatment in conditions such as psoriasis.